Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by three referees whose comments are enclosed. As you will see, all three reviewers show significant interest in your work and appreciate the high quality of the data presented. However, all three -and referee 3 in particular -raise a number of concerns that would first need to be addressed before we could consider publication of your manuscript. In particular, referee 3 is not fully convinced by your evidence that the different STT3 isoforms have different acceptor specificities, primarily based on an inaccurate calculation of isoelectric points. Clearly, it is critical that this issue is resolved. In addition, I would draw your attention to the comments of referee 1 regarding the need to make your manuscript more accessible to non-specialists, and to consider alternative explanations for the data you present.
In the light of the referees' positive recommendations, I would therefore like to invite you to submit a revised version of the manuscript, addressing all the comments of all three reviewers (particularly, but not restricted to, those highlighted above). I should add that it is EMBO Journal policy to allow only a single round of revision. Therefore, acceptance of your paper will depend on your ability to fully answer the points raised by the referees.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
REFEREE REPORTS Referee #1 (Remarks to the Author):
This paper is a major investigation of glycosylation specificity at the deep level in trypanosomes, and as such, is at a very high impact. Trypanosomes represent the best model outside of classical systems for such studies, and the work is thorough, well documented and overall convincing. My major issue is with the writing -this is very dense and compact, and there is a major assumption that the reader is on the same wavelength as the authors -this is not always true and this reviewer found that in parts she had to dig to fully appreciate the context. Further, there is a rather inflexible current running through the piece, and the possibility of alternate explanations does not seem to be well entertained, considered or mentioned in many places. This is important as EMBO is a general journal and the work needs to be made more accessible.
The potential that the STT specificity is modified by heterologous expression is not discussed -the peptide analysis in yeast is very smart and detailed, but the system there is very different, including the absence of complex class processing, the overall environment in the ER and major differences in growth rates and protein turnovers for example when compared against trypanosomes. The analysis therefore ought to be qualified a little.
The possibility that differential glycosylation is also environmental needs to be considered -i.e. distance from membrane, influenced by interactions with chaperones, and also quaternary structure?
A dot is used as opposed to delta for ko, which is confusing. Also, there is a lot of data in the yeast section -what is point of the FOA for example in the present context? Explain a little more for accessibility.
I am not sure I totally buy the argument that the differences in the glycopeptide profiles cannot be due to expression levels -presumably there is a detection limit here and a cutoff that is used for the MS analysis, which is of course appropriate, but the over-expressed trypanosome STTs could be acting more efficiently due to greater activity in general. This is not necessarily the same as total protein level.
Explain reason for doing the rnai in a heterozygote -is this for increased efficiency or other reasons?
Need to make clear that the biochemical analysis by endoH is on new VSG and the MS is on bulk material.
Could the data not also indicate that the dual oligoman form is processed, or could be processed to the mature form (wild type is not really correct here as it is a genetic term; it is VSG as made in a wold type trypanosome). the statement as read suggests that the dual oligoman form is somehow excluded from further action, and possibly degraded. Is this what the authors intend, and if so, is there other evidence to support this or is it a new model at this point? I do not find the differences to be very clear between 3C and 3D -I may be missing something but overall these do not seem so radically different. Perhaps better annotation here of the mw involved or rearranging the panels so that the corresponding surface and ER pools are adjacent would help?
In addition, the material that is analysed here is ghost and sVSG rather than, sensu stricto, ER and surface.
STTA:The authors need to also entertain the possibility here that the phenotype is secondary -for example a GTase or processing enzyme that is critical for progression to complex glycans may have been strongly affected by the altered glycosylation environment, and leads to the very huge difference inthe overall profile of glycans that are detected. I accept totally that the authors explanation is reasonable, but there are other possibilities. STTB: Again, I agree that the proposal is a good one, but I also think the same possibility, that an additional factor that is critical, could have been very strongly affected. I am not that comfortable with the idea of such exclusive function, as this is rare in such complex cases where there are so many players.
Is the pI correlation also supported by work in other organisms?
Mouse data: Why no kinetic count here for growth in mice? What time point is the count and why? Is there recovery of growth for example consistent with the rnai machinery breaking? I think this is important as the analysis presented indicates that the cells have reverted, but there is the trivial explanation that something else has affected growth here, rather than the rnai itself and the authors are just looking at revertants throughout the experiment.
No validation of the knockdown -qRTPCR? This is a critical control.
It is not true that this is the first example of essentiality in vivo and not in vitro. Why is this an issue anyway?
Referee #2 (Remarks to the Author): This is an extremely complete and thorough study of role played by different STT3 proteins of T. Brucei and tells us a lot about what they actually do. The work is of a very high technical standard and a large amount of compelling and well controlled data is presented. A key finding is the difference in the N-linked glycan that is transferred to substrate proteins by different STT3s. The context of the N-glycosylation site in influencing subsequent modification is also very clearly shown. The work is all pulled together in a very complementary and biologically relevant fashion culminating in the use of a mouse model for T. Brucei infection.
Minor comments.
1. The "deltas" have been lost throughout the text in relation to STT3 deleted yeast strains. 2. What is the definition of an efficient or poor glycosylation site as used for Figure 1 4. There seems to be something odd about Figures 3C and 4C in that the mobilities of the TbSTT3A,B,C and TbSTT3B RNAi products (-Tet) are not quite identical (assuming the samples were run on the same gel). Fig. 3C , lanes 1 and 7 should be identical but are not? Likewise Fig. 4C , lanes 1 and 7 should be that same but have apparently different mobility. The EndoH resistance of the doubly glycosylated form of ER associated VSG is also not convincing (Fig. 4C, lane 5) . 5. The proportion of EndoH sensitive and insensitive VSG in siTbSTT3A cells cannot be readilly estimated from the image since provided it the product is overexposed (Fig. 3C ). 6. What is the consequence of siTbSTT3C on VSG processing? 7. Supplementary Fig. S1 could be better labelled. 8. Page 5 refers to the "in vivo" analysis of OST function by RNAi. On page 8, this analysis becomes "in vitro". These terms can become confusing when dealing with different systems and organisms in the same manuscript. It may be better to avoid their use unless absolutely necessary. Alternatively please be entirely consistent.
Referee #3 (Remarks to the Author):
The manuscript from Izquierdo et al addresses the substrate specificity of the multiple STT3 homologues in T. brucei. The authors have discovered that 2 of 3 STT3 genes are expressed in vitro, and they present strong evidence that the two STT3 proteins use different donor oligosaccharides. The also propose that the two STT3 proteins recognize acceptor sites with different properties. The evidence here is less convincing due to errors in the calculation of protein isoelectric points. After the manuscript is revised to improve clarity and to correct the errors, it could be reconsidered.
1.
The authors suggest that the difference in ER (Fig. 3C ) and cell surface (Fig. 3D ) glycan composition of VSG221 in STT3ARNAi (+Tet) Fig. 3D is explained by more efficient cell surface expression of VSG221 that has a complex glycan on N263. I am puzzled by the low ion intensity of N263 glycopeptides that carry the high mannose glcyan in the STT3ARNAi (+Tet) cells (Table  SIV) . Are glycopeptides in Table SIV and Fig. S3 derived from total VSG221 or cell surface VSG221? If cell surface VSG221 was used for all glycan analysis (Fig. 2, Table S3, Table S4 , Fig.  S3 ), the authors should clearly state this. If this is the case, glycan analysis utilized a pool that was enriched for he wild type rather than mutant glycan structures in the TbSTT3A RNAi.
2.
I'm not sure how the authors calculated isoelectric points below 2.0 for a 14 residue peptide, since this is simply impossible. Since these peptides are embedded in a protein, the calculation should only be dependent upon the side chains (Noα-amino group on residue 1, no Cterminal carboxyl group on residue 13). Side chains (DERKHC and Y) are the only contributing factors. The most acidic side chains (D and E have pKs of ~4). Poly-aspartate (~50 D residues) has a calculated isoelectric point of about 2.5, while polyarginine has a calculated isoelectric point of 13.5, so this defines the possible range of IEPs for peptides. For this reason I am extremely skeptical that the mean pI of Tb. STT3A sites is 2.5, since that corresponds to the poly-acidic extreme of the possible range of IEP. I also don't see how one can have a variance in isoelectric point (Table SV, variance for + category =14.1) that exceeds the possible range of peptide isoelectric points. I looked at several of the peptides in the PRIDE depository, and found that the authors calculated isoelectric points are off by as much as 3 pH units. For example, a 13 residue glycopeptide (DVGALNDTAVLSE) in the file Tb05030H13.470 is listed as having an isoelectric point of 0!!, when in fact it is closer to 3.2-3.3. 3.
The authors present evidence that a single TbSTT3 is sufficient in vitro ( Fig. 3B and 4B ) and indicate that at least one STT3 is essential based upon Fig. S1F . It should be noted that the cells seem to be adapting to the double knockdown after about 120 hours. Perhaps this is due to inactivation of the RNAi construct, but this possibility has not been tested. The authors also present convincing evidence that both STT3s are required for efficient infection of animals. In this case they suggest that the surviving cells (<10% of wild type) are explained by a reduced effect of the RNAi. This hypothesis is not well supported by the digestion data ( Fig. 6C and 6D ). In the case of the STT3A RNAi, the EndoH sensitivity of cell surface VSG211 looks remarkably similar to that shown in Fig. 3D for the in vitro experiment (where there is no selection pressure to lose the knockdown construct). In the case of the STT3B RNAi (Fig. 6D) , the experiment is somewhat flawed by the observation that -Dox sample resembles the +Dox sample, rather than the wild type. One wonders whether this is an experimental error. Secondly, the possibility that there are EndoH sensitive glycans in Fig. 6D (+Dox) would need to be confirmed by ES-MS analysis. Rather than embark upon such an analysis, I suggest that the authors remove the suggestion that the surviving cells are escaping the RNAi, since they have not tested this by RT-PCR. It seems more likely that the TbSTT3s do not have 100% specificity for the donor oligosaccharide and acceptor sites, and will transfer a non-preferred donor (GlcNAc2Man5 for STT3B) at a certain frequency to the nonpreferred site (N263 for TbSTT3B).
4.
The authors would like to conclude that TbSTT3C and TbSTT3B also have different acceptor site specificities based upon the data presented in Fig. 1 . It would be nice if the authors could use the same size window (4 residues on each side of NXT/S in Fig. 1 , and 5 residues on each side in Fig.5 ) to consider the impact of adjacent residues on glycosylation efficiency. It would be preferable if the method of peptide comparison was the same in both cases (correctly calculated isoelectric point). The weakness of the Fig. 1D method is that the reader can deduce very little about the net charge of the sequences flanking poorly and efficiently modified glycosylation sites. In the case of STT3C, the number of efficiently used sites appears to be 12, while inefficient sites number 17, so any conclusions are somewhat blunted by the small number of peptides. This reviewer also wonders whether the method of analysis (use of cell surface protein) biases against the detection of certain hypoglycosylated variants, if lack of a glycan at a certain site has a negative impact on protein folding in the ER, a phenomena which is not unheard of. Efficient and inefficient sites both contain 0-3 acidic residues within this region, but it is not clear whether the poorly glycosylated outliers (2 or 3 acidic residues) have neutral PI's due to the presence of one or more basic residues. I can't help wondering whether there is a more effective and convincing way to present the data than box diagrams. For example can the authors plot glycosylation efficiency vs IEP for STT3C? The observation that the TOS1_417 site is glycosylated, albeit not with 100% efficiency, by Tb SXTT3B, but not by yeast OST is interesting. There is some statistical evidence from B. Imperiali's lab that lysine at +4 relative to N in the sequon is underrepresented in sequon databases. Supplemental Section 1. Table S1 . (a) An asparagine in the glycopeptide CCW14_87 (m/z = 1105.4781) is marked by an asterisk, presumably indicating that this site is glycosylated. This seems to be the only asparagine marked by an asterisk; N residues in other glycopeptides appear to be in a bold font. Is there some reason that this peptide is marked differently? (b)
The significance of the Rank column is unclear since all peptides are entries are ranked 1.
(c) #Previously identified15. The meaning of the superscript 15 is not clear.
The authors should add a sentence beneath the table to define the score column. Why does the peptide GAS1_253* have a score of (68) (i.e. score within parentheses) (e)
The expect column should also be defined. It is not clear why the exponent is capitalized in some cases (i.e. 8.4E-04), but not in others (i.e. 8.2e-08).
The glycopeptide EXG2_50 should have an asterisk after it.
2. Figure S3 and Table SIV . Each of these supplemental items contains information on the glycan structure of pronase peptides derived from VSG221 produced by T. brucei cells that express TbSTT3A, TbSTT3B or TbSTT3A+TbSTT3B. It is not clear to me why some intensity data presented in Figure S3 is in conflict with tabulated data in Table SIV . As an example, consider FigS3, panel A, N263 glycopeptide NET (Hex3HexNAc2). Figure S3 shows a 60% intensity value for this glycopeptide in both the -Tet and +Tet conditions. However, ion intensity values in Table  SIV for this peptide ({plus minus}Tet in STTA siRNA) are 439.4 (-Tet) and 173.4 (+Tet). The S3 figure legend does not explain how % intensity values were calculated, but it seems likely that the Table SIV values were normalized to the intensity of another glycopeptide. At best, Fig. S3A is confusing, because it appears that siRNA knockdown of STT3A does not reduce transfer of the GlcNAc2Man5 to the N263, but instead increases transfer of GclcNAc2Man9 to the N428 site.
3. Figure S4 . This figure could be expanded to show the source of glycoproteins (total glycoprotiens or cell surface glycoproteins?) and to indicate whether the samples used for digestion were enriched by sequential lectin chromatography (ConA and then ricin) or split sample chromatography (ConA or ricin).
Minor points:
1.
The Schulz and Aebi reference is listed twice in the References list, once in 2008 (no Vol and page #) and once in 2009. 2.
Legend Fig. 1(C) , the sentence "Data is shown in Table S1 " should read "Data is shown in Table S2 . " 3.
Define symbols used in in Fig. 2 (GlcNac, Man, etc.) 4.
The manuscript should mention that results of the proteomics analysis of T. brucei glycopeptides is available in the PRIDE database (list accession #). Hopefully they will correct the annotated IEPs. Referee #1 (Remarks to the Author): This paper is a major investigation of glycosylation specificity at the deep level in trypanosomes, and as such, is at a very high impact. Trypanosomes represent the best model outside of classical systems for such studies, and the work is thorough, well documented and overall convincing. My major issue is with the writing -this is very dense and compact, and there is a major assumption that the reader is on the same wavelength as the authors -this is not always true and this reviewer found that in parts she had to dig to fully appreciate the context. Further, there is a rather inflexible current running through the piece, and the possibility of alternate explanations does not seem to be well entertained, considered or mentioned in many places. This is important as EMBO is a general journal and the work needs to be made more accessible.
>>>> We accept this criticism and have written a more expansive introduction and discussion, including providing alternative explanations, to address it.
The potential that the STT specificity is modified by heterologous expression is not discussed -the peptide analysis in yeast is very smart and detailed, but the system there is very different, including the absence of complex class processing, the overall environment in the ER and major differences in growth rates and protein turnovers for example when compared against trypanosomes. The analysis therefore ought to be qualified a little. (Castro et al. 2006; Nasab et al. 2008; Hese et al. 2009) (Shams-Eldin et al. 2005; Castro et al. 2006; Nasab et al. 2008; Hese et al. 2009 ).
>>>> We accept this criticism. The heterologous expression system using yeast has been used successfully before to analyze the activity of T.cruzi and Leishmania STT3s
The possibility that differential glycosylation is also environmental needs to be considered -i.e. distance from membrane, influenced by interactions with chaperones, and also quaternary structure? I am not sure I totally buy the argument that the differences in the glycopeptide profiles cannot be due to expression levels -presumably there is a detection limit here and a cutoff that is used for the MS analysis, which is of course appropriate, but the over-expressed trypanosome STTs could be acting more efficiently due to greater activity in general. This is not necessarily the same as total protein level. (Shams-Eldin et al. 2005; Castro et al. 2006; Nasab et al. 2008; Hese et al. 2009 (Cross, 1975 (Cross, , 1984 Ferguson et al, 1985) . et al, 2005; Urbaniak et al, 2006; Manthri et al, 2008; Stokes et al 2008 
This cell surfacederived sVSG221 is amenable to glycoform analysis as an intact glycoprotein by ES-MS and as Pronase glycopeptides by ES-MS and ES-MS/MS (Jones

>>>> The reviewer is correct to point out this out. The revised and extended version explains the situation much more clearly and explains the data in our previous paper, derived from both bioinformatics analyses and experimental analyses using alphamannosidease inhibitors, that indicate that: "As noted previously (Manthri et al. 2008), the strict demarcation between these different routes to complex and oligomannose N-glycans appears to be due to the absence of the Golgi mannosidase II activity that permits the conversion of triantennary Man5GlcNAc2 to Man3GlcNAc2 in other eukaryotes." This statement is now in the discussion.
I do not find the differences to be very clear between 3C and 3D -I may be missing something but overall these do not seem so radically different. Perhaps better annotation here of the mw involved or rearranging the panels so that the corresponding surface and ER pools are adjacent would help?
We understand the reviewer's point but this is exactly why the data in Fig. 3D are also obtained backed up by ES-MS of the whole VSG and ES-MS and ES-MS/MS of their Pronase glycopeptides.
In addition, the material that is analysed here is ghost and sVSG rather than, sensu stricto, ER and surface. (Cross, 1975 (Cross, , 1984 Ferguson et al, 1985) .
>>>> We will stick to the existing descriptions but have added the following explanation in the text: "Cell surface VSG can be purified in a soluble form (sVSG221) after osmotic shock, a process that releases VSG from the parasite surface by the action of endogenous GPI-specific phospholipase C that cleaves the dimyristoylglycerol lipid component of the VSG GPI anchor
This cell surface-derived sVSG221 is amenable to glycoform analysis as an intact glycoprotein by ES-MS and as Pronase glycopeptides by ES-MS and ES-MS/MS (Jones et al, 2005; Urbaniak et al, 2006; Manthri et al, 2008; Stokes et al 2008). In addition, the N-glycosylation status of both cell surface-derived sVSG221 and of newly-synthesized (presumably ER-associated) VSG221, i.e., that which is not released by osmotic shock (Ferguson et al 1985), can be assessed by EndoH and PNGaseF digestion and analysis by SDS-PAGE and Coomassie blue staining or Western blot, respectively."
>>>> We think that the revised version provides more balanced arguments than the original and we thank the reviewer for asking us to do this.
Mouse data: Why no kinetic count here for growth in mice? What time point is the count and why? Is there recovery of growth for example consistent with the rnai machinery breaking? I think this is important as the analysis presented indicates that the cells have reverted, but there is the trivial explanation that something else has affected growth here, rather than the rnai itself and the authors are just looking at revertants throughout the experiment. Mol Biochem Parasitol. (2003) Feb; 126(2):275-9 .
>>>> As I am sure the reviewer appreciates, there are many ways to perform in vivo gene essentiality for T.brucei and that there is some debate about the "best" protocol. The protocol we favour because, in our opinion, of its simplicity and clarity is that performed here ñ i.e., we perform an acute infection in groups of 5 mice and measure parasitaemia 3 days later (apologies for not stating this previously). Thus, the control animals show robust parasitaemias (mean levels around 5 x 108 parasites per ml of blood) with which to compare the doxycline-induced knockdown parasitaemia. Our experience with a number of cell lines has shown that measurement before 3 days will give unmeasurably low parasitaemias if the gene is essential while taking measurements beyond 3 days simply selects for the inevitable RNAi escape mutants*. At the 3 day time point, RNAi knockdown of essential genes gives the result seen here, i.e., (a) an obvious reduction on parasitaemia (to <0.5 x 108 per ml) if the gene is essential and (b) sufficient cells to do some biochemical phenotyping (in this case the Western blots ± glycosidase treatments) to ascertain whether these few surviving cells are tending to wild
No validation of the knockdown -qRTPCR? This is a critical control. (Fig. 3A and 4A ). The work is all pulled together in a very complementary and biologically relevant fashion culminating in the use of a mouse model for T. Brucei infection.
>>>> We believe that Northern blot, as well as qRTPCR, is a good validation assay for the knockdowns of TbSTT33A and TbSTT3B
1. The "deltas" have been lost throughout the text in relation to STT3 deleted yeast strains.
>>>> The conversion of deltas to dots was a pdf conversion artefact -we apologise to the reviewers for not picking it up.
2. What is the definition of an efficient or poor glycosylation site as used for Figure 1? >>>> In material and methods, just at the end of 'Site-specific glycosylation occupancy determination' we have added the sentence: "Glycosylation sites with more than 95% occupancy were defined as being "efficiently" glycosylated."
3. The basis for identifying specific oligosaccharides could be better stated in the legend to Figure 2 .
>>>> We agree and have re-written the figure legend as follows: "Fig. 2. Mass spectrometric analyses of intact mature sVSG221 glycoforms before and after selective knockdown of TbSTT3A and TbSTT3B expression. Samples of sVSG221 were analyzed by ES-MS. The spectra show the masses of the various glycoforms of the intact mature sVSG221 molecules. The inset cartoons represent our interpretation of those glycoform masses in terms of the ranges of Nglycans present at each of the two N-glycosylation sites. These assignments combine additional data from the ES-MS and ES-MS/MS analyses of Pronase glycopeptides from the same sVSG221 preparations (Fig. S3 and Table SIV). In the inset cartoons, endo-H-resistant N-glycans are in red and endo-H-sensitive N-glycans are in blue. Filled circles and squares (red or blue) represent mannose and N-acetylglucosmaine residues, respectively, and open circles represent galactose residues. "
4. There seems to be something odd about Figures 3C and 4C in that the mobilities of the TbSTT3A,B,C and TbSTT3B RNAi products (-Tet) are not quite identical (assuming the samples were run on the same gel). Fig. 3C , lanes 1 and 7 should be identical but are not? Likewise Fig. 4C , lanes 1 and 7 should be that same but have apparently different mobility. The EndoH resistance of the doubly glycosylated form of ER associated VSG is also not convincing (Fig. 4C, lane 5) .
>>>> The samples for each panel were run on the same gel. We have rotated the image in Fig 4C
by minus 3° to compensate for gel "smiling". The other differences (eg. Fig. 3C lanes 1 and 7) are due to slightly different loadings and/or transference during Western blotting. This is the best we can do, bearing in mind we are looking at the differences in migration of 50 kDa glycoproteins ± 1.5 kDa glycans. For information, the images shown are representative of several (>4) independent experiments.
5. The proportion of EndoH sensitive and insensitive VSG in siTbSTT3A cells cannot be readilly estimated from the image since provided it the product is overexposed (Fig. 3C) . Fig 3C lane 7. Supplementary Fig. S1 could be better labelled.
>>>> We do not agree. Eg. all of the signal shifts in
>>>> We agree and this has been done and the figure legend improved as well.
8. Page 5 refers to the "in vivo" analysis of OST function by RNAi. On page 8, this nalysis becomes "in vitro". These terms can become confusing when dealing with different systems and organisms in the same manuscript. It may be better to avoid their use unless absolutely necessary. Alternatively please be entirely consistent.
>>>> This is a good point and we have replaced "in vivo" with "in trypanosomes" and "in vitro"
with "in culture" whenever these are the meanings we wish to convey.
1. The authors suggest that the difference in ER (Fig. 3C ) and cell surface (Fig. 3D ) glycan composition of VSG221 in STT3ARNAi (+Tet) Fig. 3D is explained by more efficient cell surface expression of VSG221 that has a complex glycan on N263. I am puzzled by the low ion intensity of N263 glycopeptides that carry the high mannose glcyan in the STT3ARNAi (+Tet) cells (Table  SIV) . Are glycopeptides in Table SIV and Fig. S3 derived from total VSG221 or cell surface VSG221? If cell surface VSG221 was used for all glycan analysis (Fig. 2 , Table S3, Table S4 , Fig.  S3 ), the authors should clearly state this. If this is the case, glycan analysis utilized a pool that was enriched for he wild type rather than mutant glycan structures in the TbSTT3A RNAi. Table SIV and Fig. S3 as well as in Fig. 2 and Fig. 3C and Fig. 3D (Blum et al, 1993; Izquierdo et al, 2009 )."
>>>> All MS glycopeptide analyses, i.e., those in
2. I'm not sure how the authors calculated isoelectric points below 2.0 for a 14 residue peptide, since this is simply impossible. Since these peptides are embedded in a protein, the calculation should only be dependent upon the side chains ((Noα-amino group on residue 1, no C-terminal carboxyl group on residue 13). Side chains (DERKHC and Y) are the only contributing factors. The most acidic side chains (D and E have pKs of ~4). Poly-aspartate (~50 D residues) has a calculated isoelectric point of about 2.5, while polyarginine has a calculated isoelectric point of 13.5, so this defines the possible range of IEPs for peptides. For this reason I am extremely skeptical that the mean pI of Tb. STT3A sites is 2.5, since that corresponds to the poly-acidic extreme of the possible range of IEP. I also don't see how one can have a variance in isoelectric point ( 3. The authors present evidence that a single TbSTT3 is sufficient in vitro ( Fig. 3B and 4B ) and indicate that at least one STT3 is essential based upon Fig. S1F . It should be noted that the cells seem to be adapting to the double knockdown after about 120 hours. Perhaps this is due to inactivation of the RNAi construct, but this possibility has not been tested. The authors also present convincing evidence that both STT3s are required for efficient infection of animals. In this case they suggest that the surviving cells (<10% of wild type) are explained by a reduced effect of the RNAi. This hypothesis is not well supported by the digestion data ( Fig. 6C and 6D ). In the case of the STT3A RNAi, the EndoH sensitivity of cell surface VSG211 looks remarkably similar to that shown in Fig. 3D for the in vitro experiment (where there is no selection pressure to lose the knockdown construct). In the case of the STT3B RNAi (Fig. 6D) , the experiment is somewhat flawed by the observation that -Dox sample resembles the +Dox sample, rather than the wild type. One wonders whether this is an experimental error. Secondly, the possibility that there are EndoH sensitive glycans in Fig. 6D (+Dox) would need to be confirmed by ES-MS analysis. Rather than embark upon such an analysis, I suggest that the authors remove the suggestion that the surviving cells are escaping the RNAi, since they have not tested this by RT-PCR. It seems more likely that the TbSTT3s do not have 100% specificity for the donor oligosaccharide and acceptor sites, and will transfer a non-preferred donor (GlcNAc2Man5 for STT3B) at a certain frequency to the nonpreferred site (N263 for TbSTT3B). Mol Biochem Parasitol. (2003) 126: 275-9.) We also acknowledge the complexity and "imperfection" of Figure 6D (lanes 7-9) 4. The authors would like to conclude that TbSTT3C and TbSTT3B also have different acceptor site specificities based upon the data presented in Fig. 1 . It would be nice if the authors could use the same size window (4 residues on each side of NXT/S in Fig. 1 , and 5 residues on each side in Fig.5 ) to consider the impact of adjacent residues on glycosylation efficiency. It would be preferable if the method of peptide comparison was the same in both cases (correctly calculated isoelectric point).
>>>>
The weakness of the Fig. 1D method is that the reader can deduce very little about the net charge of the sequences flanking poorly and efficiently modified glycosylation sites. In the case of STT3C, the number of efficiently used sites appears to be 12, while inefficient sites number 17, so any conclusions are somewhat blunted by the small number of peptides. This reviewer also wonders whether the method of analysis (use of cell surface protein) biases against the detection of certain hypoglycosylated variants, if lack of a glycan at a certain site has a negative impact on protein folding in the ER, a phenomena which is not unheard of. Efficient and inefficient sites both contain 0-3 acidic residues within this region, but it is not clear whether the poorly glycosylated outliers (2 or 3 acidic residues) have neutral PI's due to the presence of one or more basic residues. I can't help wondering whether there is a more effective and convincing way to present the data than box 
>>>> This has been added.
(f) The glycopeptide EXG2_50 should have an asterisk after it.
>>>> Corrected.
2. Figure S3 and Table SIV . Each of these supplemental items contains information on the glycan structure of Pronase peptides derived from VSG221 produced by T. brucei cells that express TbSTT3A, TbSTT3B or TbSTT3A+TbSTT3B. It is not clear to me why some intensity data presented in Figure S3 is in conflict with tabulated data in Table SIV . As an example, consider FigS3, panel A, N263 glycopeptide NET (Hex3HexNAc2). Figure S3 shows a 60% intensity value for this glycopeptide in both the -Tet and +Tet conditions. However, ion intensity values in Table  SIV for this peptide ({plus minus}Tet in STTA siRNA) are 439.4 (-Tet) and 173.4 (+Tet). The S3 figure legend does not explain how % intensity values were calculated, but it seems likely that the Table SIV values were normalized to the intensity of another glycopeptide. At best, Fig. S3A is confusing, because it appears that siRNA knockdown of STT3A does not reduce transfer of the GlcNAc2Man5 to the N263, but instead increases transfer of GclcNAc2Man9 to the N428 site.
>>>> We apologise for the lack of clarity (now improved in the legends to Table SIV and legend to Fig. S3 ). The figures in Table SIV are the raw data (ion counts) for each glycopeptide ion and the % intensities in Figure S3 are normalized to the intensity of the most intense glycopeptide ion in each analysis. Thus, using the refereeís example, for N263 glycopeptide NET(Hex3HexNAc2) the intensities of 439.4 (-Tet) and 173.4 (+Tet) are normalized to 724.3 (-Tet, intensity of GPI anchor+5Gal) and to 294.7 (+Tet, NTT+NaHex9HexNAc2), respectively. The purpose of retaining both of these somewhat redundant data sets is (a) to not loose sight of the raw data (Table SIV) and (b) to provide a graphic image (Fig. S3 ) that allows one to observe clearly how the NET site gets Man8 and Man9 glycans in the STT3A siRNA +Tet cells and not in the -Tet cells and how the NTT site gets abundant complex glycans in the STT3B siRNA +Tet cells and few in the -Tet cells.
3. Figure S4 . This figure could be expanded to show the source of glycoproteins (total glycoprotiens or cell surface glycoproteins?) and to indicate whether the samples used for digestion were enriched by sequential lectin chromatography (ConA and then ricin) or split sample chromatography (ConA or ricin). 2. Legend Fig. 1(C) , the sentence "Data is shown in Table S1 " should read "Data is shown in Table  S2 . " >>>> Corrected.
>>>> The figure has been improved and also the following has been inserted into the results
3. Define symbols used in in Fig. 2 (GlcNac, Man, etc.)
>>>> Done.
4. The manuscript should mention that results of the proteomics analysis of T. brucei glycopeptides is available in the PRIDE database (list accession #). Hopefully they will correct the annotated IEPs.
>>>> The PRIDE entries have been corrected for IEPs and the accession number is now quoted in the paper
